I-Mab In Talks With Pharma Giants About Partnership, Stake Sale: Bloomberg
A year after I-Mab (NASDAQ:IMAB) made headlines with its $2.9 billion deal licensing a CD47 drug to AbbVie Inc (NYSE:ABBV), the biotech…
Why Are I-Mab Shares Trading Higher On Tuesday?
The Center for Drug Evaluation of China National Medical Products Administration has signed off I-Mab’s (NASDAQ:IMAB) IND application to initiate a…
48 Biggest Movers From Friday
Gainers
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by AstraZeneca for patients with unresectable, stage 3 non-small cell lung cancer.
25 Stocks Moving In Friday’s Mid-Day Session
Gainers
Helbiz, Inc. (NASDAQ: HLBZ) shares jumped 92.7% to $17.35 after the company announced its media unit has entered into an agreement with FOX Networks to broadcast the Italian Serie B championship across the USA and the Caribbean.
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 26)
I-Mab To Start Testing Alzheimer’s Candidate In Human Trials
The FDA has signed off I-Mab (NASDAQ:IMAB) Investigational New Drug (IND) application for Protollin, an Alzheimer’s candidate. Brigham and Women’s Hospital…
ABL Bio Announces Publication of Preclinical Data Of ABL503/TJ-L14B. BZ NOTE: ABL503 Was Jointly Developed With I-Mab
ABL Bio, Inc. (KOSDAQ: 298380), a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, today announced the publication of pre-clinical data